… Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both
… Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains …

… could improve the prognosis of colorectal cancer (CRC) patients… However, drug resistance
significantly reduces the usefulness … may be a promising target for reversing tumor resistance. …

… Tumor microenvironment, Immunotherapy, Checkpoint inhibitors, Microbiome Core tip: Therapy
resistance has been a culprit for colorectal cancer … overcome common drug resistance. In …

… rates and overall survival however resistance to these drugs is inevitable. Novel … resistance
and methods to overcome treatment resistance in patients with metastatic colorectal cancer …

… Colorectal cancer (CRC) is the third most common cancer in the world. Although there
are standard treatment options for CRC, most patients respond poorly to these treatments. …

… , tumors with mismatch-repair deficiency (dMMR) (10–20%) of advanced colorectal cancer …
infiltrates than mismatch-repair-proficient colorectal cancers (pMMR), a finding consistent with …

… Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide,
with around 1.9 million new cases and more than 935,000 deaths in 2020 [1]. Significant …

… cancer stem cells in mediating cellular drug resistance and … polyposis and hereditary
nonpolyposis colorectal cancer, the 2 … Hereditary nonpolyposis colorectal cancer accounts for …

… heterogeneity, arising as a result of acquired resistance, on response to subsequent lines of
… patient with colorectal cancer display genetically distinct mechanisms of resistance to EGFR …

… circulating tumor DNA (ctDNA) to genotype colorectal tumors … with primary or acquired
resistance to EGFR blockade in the … cells that had acquired resistance to cetuximab reveals that …